Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures

Molecular Cancer Research

Volumn 11, Issue 6, 2013, Pages 676-685

  Federici, Giulia ^a,c   Gao, Xi ^d   Slawek, Janusz ^d   Arodz, Tomasz ^d   Shitaye, Amanuel ^c   Wulfkuhle, Julia D ^c   De Maria, Ruggero ^b   Liotta, Lance A ^c   Petricoin III, Emanuel F ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c GEORGE MASON UNIVERSITY   (United States)

^d Virginia Commonwealth University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRIN; ISOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; PHOSPHOPROTEIN; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL PROLIFERATION; HUMAN; HUMAN CELL; MIGRATION; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; SURVIVAL; SYSTEM ANALYSIS; TREATMENT RESPONSE;

CELL LINE, TUMOR; CLUSTER ANALYSIS; HUMANS; INTEGRINS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84879297435     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0690     Document Type: Article

References (37)

1. Holbeck SL, Collins JM, Doroshow JH. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 2010;9:1451-60.
2. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-12.
3. Sausville EA, Holbeck SL. Transcription profiling of gene expression in drug discovery and development: the NCI experience. Eur J Cancer 2004;40:2544-9.
4. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogeneamplified in malignant melanoma. Nature 2005;436:117-22.
5. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007;6:1483-91.
6. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003;100:14229-34.
7. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-47.
8. Myers TG, Anderson NL, Waltham M, Li G, Buolamwini JK, Scudiero DA, et al. A protein expression database for the molecular pharmacology of cancer. Electrophoresis 1997;18:647-53.
9. Improta G, Zupa A, Fillmore H, Deng J, Aieta M, Musto P, et al. Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J Proteome Res 2011;10:3089-97.
10. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 2010;9:257-67.
11. Available from: http://discover.nci.nih.gov/cellminer/. Accessed 4/26/2013.
12. Available from: http://dtp.nci.nih.gov. Accessed 4/26/2013.
13. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R, et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinfor-matics 2006;7 Suppl 1:S7.
14. Faith JJ, Hayete B, Thaden JT, Mogno I, Wierzbowski J, Cottarel G, et al. Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol 2007;5:e8.
15. Meyer PE, Kontos K, Lafitte F, Bontempi G. Information-theoretic inference of large transcriptional regulatory networks. EURASIP J Bioinform Syst Biol 2007:79879.
16. Altay G, Emmert-Streib F. Inferring the conservative causal core of gene regulatory networks. BMC Syst Biol 2010;4:132.
17. Huynh-Thu VA, Irrthum A, Wehenkel L, Geurts P. Inferring regulatory networks from expression data using tree-based methods. PLoS ONE 2010;5.
18. Mammano E, Galdi F, Pierobon M, Tessari E, Deng J, Pucciarelli S, et al. Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. Clin Colorectal Cancer 2012;11:268-74.
19. Bao Y, Hata Y, Ikeda M, Withanage K. Mammalian Hippo pathway: from development to cancer and beyond. J Biochem 2011;149:361-79.
20. Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008;13:188-92.
21. Wang FE, Zhang C, Maminishkis A, Dong L, Zhi C, Li R, et al. MicroRNA-204/211 alters epithelial physiology. FASEB J 2010;24: 1552-71.
22. Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 2012;26:1829-41.
23. Cinar B, Fang PK, Lutchman M, Di Vizio D, Adam RM, Pavlova N, et al. The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J 2007;26:4523-34.
24. Bertini E, Oka T, Sudol M, Strano S, Blandino G. YAP: at the crossroad between transformation and tumor suppression. Cell Cycle 2009;8: 49-57.
25. Duque-Afonso J, Yalcin A, Berg T, Abdelkarim M, Heidenreich O, Lubbert M. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene 2011;30:3062-72.
26. Jang SW, Yang SJ, Srinivasan S, Ye K. Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J Biol Chem 2007;282:30836-44.
27. Lee KK, Yonehara S. Identification of mechanism that couples multisite phosphorylation of Yes-associated protein (YAP) with transcriptional coactivation and regulation of apoptosis. J Biol Chem;287:9568-78.
28. Ling P, Lu TJ, Yuan CJ, Lai MD. Biosignaling of mammalian Ste20-related kinases. Cell Signal 2008;20:1237-47.
29. Xiao L, Chen D, Hu P, Wu J, Liu W, Zhao Y, et al. The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J Neurosci 2011;31:9611-9.
30. Meenhuis A, van Veelen PA, de Looper H, van Boxtel N, van den Berge IJ, Sun SM, et al. MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. Blood 2011;118:916-25.
31. Nishida N, Nagahara M, Sato T, Mimori K, Sudo T, Tanaka F, et al. Microarray analysis of colorectal cancer stromal tissue reveals upre-gulation of two oncogenic miRNA clusters. Clin Cancer Res 2011; 18:3054-70.
32. Li L, Shi JY, Zhu GQ, Shi B. MiR-17-92 cluster regulates cell proliferation and collagen synthesis by targeting TGFβ pathway in mouse palatal mesenchymal cells. J Cell Biochem 2012;113:1235-44.
33. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integ-rin-beta8. Oncogene 2011;30:806-21.
34. Available from: http://mirdb.org/cgi-bin/search.cgi?searchType= miRNA&full=mirbase&searchBox=MIMAT0000093. Accessed4/26/2013.
35. Janku F, Broaddus R, Bakkar R, Hong DS, Stepanek VMT, Naing A, et al. PTEN assessment and PI3K/mTOR inhibitors: importance of simultaneous assessment of MAPK pathway aberrations. J Clin Oncol 30;2012 (suppl; abstr 10510).
36. Zuurbier L, Petricoin EF III, Vuerhard MJ, Calvert V, Kooi C, Buijs-Gladdines JG, et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica 2012; 97:1405-13.
37. van Iersel MP, Kelder T, Pico AR, Hanspers K, Coort S, Conklin BR, et al. Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics 2008;9:399.